Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | CAR T-cell therapy expectations for myeloma

Nina Shah • 14 Sep 2019
IMW 2019
Multiple Myeloma AMG 420 bb2121 CAR-T

Nina Shah, MD, from the University of California, San Francisco, CA, discusses whether CAR T-cell therapy is meeting expectations in myeloma at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals